Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04807439 · ClinicalTrials.gov registry record
A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent System
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 100
- Enrollment target
NCT04807439: Completed study, sponsored by Boston Scientific Corporation.
NCT04807439 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04807439 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
This is a post-market, standard of care, real-world observational study to assess the clinical outcomes of the SYNERGY XLV (MEGATRON) Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 28 mm in length (by visual estimate) in native coronary arteries ≥3.50 mm to ≤5.00 mm in diameter (by visual estimate). This Post Approval study is a cohort associated with the Evolve 4.5/5.0 (SYNERGY LV) Post Approval Study, which is registered under ClinicalTrials.gov ID: NCT03875651.
Primary Outcome
12-month Target Lesion Failure (TLF) rate, defined as any ischemia driven revascularization of the target lesion (TLR), myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel, or cardiac death.
Interventions
- DEVICE SYNERGY XLV (Megatron) Coronary Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2023-08-18 |
What the finished NCT04807439 record still lists
NCT04807439 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which SYNERGY XLV (Megatron) Coronary Stent System is the first listed.
NCT04807439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04807439 about?
NCT04807439 is a clinical study titled "A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent System". This is a post-market, standard of care, real-world observational study to assess the clinical outcomes of the SYNERGY XLV (MEGATRON) Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 28 mm in length (by visual estimate) in native coronary arteries ≥3.50 mm to ≤5.0...
What is the current status of trial NCT04807439?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2021-04-14. Estimated completion is 2023-08-18.
What interventions are being tested in trial NCT04807439?
The interventions under investigation include: SYNERGY XLV (Megatron) Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT04807439?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI